{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:41:36Z","timestamp":1793256096254,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Investigator Fellowship of the National Health and Medical Research Council of Australia"},{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health"},{"name":"Riley Children\u2019s Foundation and the Indiana University Dance Marathon endowment to the Ryan White Center for Pediatric Infectious Diseases and Global Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Defining antibody correlates of protection against clinical malaria in areas of low and unstable transmission is challenging because of limited malaria cases in these areas. Additionally, clinical malaria affects both adults and children in areas of low and unstable transmission, but it is unclear whether antibody correlates of protection against malaria differ with age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Blood samples were obtained from 5753 individuals in Kenyan highland area with low and seasonal malaria transmission in 2007 and recorded episodes of clinical malaria in this population from 2007 to 2017. Using a nested case\u2013control study design, participants who developed clinical malaria (cases) were matched by age and village to those who did not (controls). Immunoglobulin (Ig)G, IgG1, IgG3, IgA and IgM responses to 16\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      antigens were compared in individuals\u2009&lt;\u20095\u00a0years old (80 cases vs. 240 controls), 5\u201314\u00a0years old (103 cases vs. 309 controls) and\u2009\u2265\u200915\u00a0years old (118 cases vs. 354 controls). Antibody level was correlated with risk of clinical malaria, adjusted for malaria exposure markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In all age groups, most antibodies were not associated with risk of clinical malaria. In children\u2009&lt;\u20095\u00a0years, higher levels of IgG to GLURP-R2 and MSP-2, IgG1 to GLURP-R2, and IgG3 to MSP-2 were associated with reduced risk of clinical malaria, while higher IgG3 levels to CSP were associated with increased risk of clinical malaria. In children 5\u201314\u00a0years and individuals\u2009\u2265\u200915\u00a0years, higher antibody levels to multiple\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      antigens were associated with an increased risk of clinical malaria, and none were associated with decreased risk of clinical malaria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antibody correlates of protection against clinical malaria were observed only in children\u2009&lt;\u20095\u00a0years old in this area of low and unstable malaria transmission. In older children and adults in this area, some antibody responses correlated with increased risk of clinical malaria. Future studies in low malaria transmission areas should evaluate the comparative contributions of cellular and humoral immunity to protection from clinical malaria in young children versus older children and adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-025-05300-1","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T22:32:06Z","timestamp":1741041126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antibody correlates of risk of clinical malaria in an area of low and unstable malaria transmission in western Kenya"],"prefix":"10.1186","volume":"24","author":[{"given":"Eliud O.","family":"Odhiambo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagan A.","family":"Mellencamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartholomew N.","family":"Ondigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E. S.","family":"Hamre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Beeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Herbert","family":"Opi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Narum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ayodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandy C.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"5300_CR1","unstructured":"WHO. World Malaria Report 2023. Geneva, World Health Organization, 2023. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023. 2023."},{"key":"5300_CR2","first-page":"2019","volume-title":"at a glance","author":"WHO. World Malaria Report","year":"2019","unstructured":"WHO. World Malaria Report. at a glance. Geneva: World Health Organization; 2019. p. 2019. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/world-malaria-report-2019."},{"key":"5300_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3184\/003685009X440290","volume":"92","author":"JG Breman","year":"2009","unstructured":"Breman JG. Eradicating malaria. Sci Prog. 2009;92:1\u201338.","journal-title":"Sci Prog"},{"key":"5300_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-3156.2009.02287.x","volume":"14","author":"K Mendis","year":"2009","unstructured":"Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH. From malaria control to eradication: the WHO perspective. Trop Med Int Health. 2009;14:802\u20139.","journal-title":"Trop Med Int Health"},{"key":"5300_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1128\/CMR.00025-08","volume":"22","author":"DL Doolan","year":"2009","unstructured":"Doolan DL, Doba\u00f1o C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13\u201336.","journal-title":"Clin Microbiol Rev"},{"key":"5300_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1017\/S0031182015001778","volume":"143","author":"A Barry","year":"2016","unstructured":"Barry A, Hansen D. Naturally acquired immunity to malaria. Parasitology. 2016;143:125\u20138.","journal-title":"Parasitology"},{"key":"5300_CR7","unstructured":"Kinyanjui S. The immunology of malaria. In: Okwa OO (ed.); Malaria parasites. IntechOpen. 2012"},{"key":"5300_CR8","doi-asserted-by":"crossref","unstructured":"Kimenyi KM, Wamae K, Ochola-Oyier LI. Understanding P. falciparum asymptomatic infections: a proposition for a transcriptomic approach. Front Immunol. 2019;10:2398.","DOI":"10.3389\/fimmu.2019.02398"},{"key":"5300_CR9","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/srep03549","volume":"3","author":"PL Felgner","year":"2013","unstructured":"Felgner PL, Roestenberg M, Liang L, Hung C, Jain A, Pablo J, et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep. 2013;3:3549.","journal-title":"Sci Rep"},{"key":"5300_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijpara.2012.03.011","volume":"42","author":"V Offeddu","year":"2012","unstructured":"Offeddu V, Thathy V, Marsh K, Matuschewski K. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int J Parasitol. 2012;42:535\u201348.","journal-title":"Int J Parasitol"},{"key":"5300_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4269\/ajtmh.2005.73.222","volume":"73","author":"CC John","year":"2005","unstructured":"John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg. 2005;73:222\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"5300_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1086\/526787","volume":"197","author":"CC John","year":"2008","unstructured":"John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, et al. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis. 2008;197:519\u201326.","journal-title":"J Infect Dis"},{"key":"5300_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040320","volume":"4","author":"C Roussilhon","year":"2007","unstructured":"Roussilhon C, Oeuvray C, M\u00fcller-Graf C, Tall A, Rogier C, Trape JF, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med. 2007;4: e320.","journal-title":"PLoS Med"},{"key":"5300_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1128\/IAI.72.1.247-252.2004","volume":"72","author":"S Soe","year":"2004","unstructured":"Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun. 2004;72:247\u201352.","journal-title":"Infect Immun"},{"key":"5300_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4269\/ajtmh.1998.58.406","volume":"58","author":"RR Taylor","year":"1998","unstructured":"Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg. 1998;58:406\u201313.","journal-title":"Am J Trop Med Hyg"},{"key":"5300_CR16","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1086\/656413","volume":"51","author":"JS Richards","year":"2010","unstructured":"Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis. 2010;51:e50-60.","journal-title":"Clin Infect Dis"},{"key":"5300_CR17","doi-asserted-by":"publisher","first-page":"33094","DOI":"10.1038\/srep33094","volume":"6","author":"R Weaver","year":"2016","unstructured":"Weaver R, Reiling L, Feng G, Drew DR, Mueller I, Siba PM, et al. The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Sci Rep. 2016;6:33094.","journal-title":"Sci Rep"},{"key":"5300_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1128\/IAI.01147-07","volume":"76","author":"I Nebie","year":"2008","unstructured":"Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso. West Africa Infect Immun. 2008;76:759\u201366.","journal-title":"West Africa Infect Immun"},{"key":"5300_CR19","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1128\/iai.60.4.1473-1481.1992","volume":"60","author":"H Bouharoun-Tayoun","year":"1992","unstructured":"Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun. 1992;60:1473\u201381.","journal-title":"Infect Immun"},{"key":"5300_CR20","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1128\/IAI.01585-07","volume":"76","author":"FHA Osier","year":"2008","unstructured":"Osier FHA, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KKA, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008;76:2240\u20138.","journal-title":"Infect Immun"},{"key":"5300_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/infdis\/jiad115","volume":"228","author":"N Nziza","year":"2023","unstructured":"Nziza N, Tran TM, DeRiso EA, Dolatshahi S, Herman JD, de Lacerda L, et al. Accumulation of neutrophil phagocytic antibody features tracks with naturally acquired immunity against malaria in children. J Infect Dis. 2023;228:759\u201368.","journal-title":"J Infect Dis"},{"key":"5300_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12916-018-1054-2","volume":"16","author":"L Kurtovic","year":"2018","unstructured":"Kurtovic L, Behet MC, Feng G, Reiling L, Chelimo K, Dent AE, et al. Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Med. 2018;16:61.","journal-title":"BMC Med"},{"key":"5300_CR23","doi-asserted-by":"crossref","unstructured":"Boyle MJ, Chan JA, Handayuni I, Reiling L, Feng G, Hilton A, et al. IgM in human immunity to Plasmodium falciparum malaria. Sci Adv. 2019;5:eaax4489.","DOI":"10.1126\/sciadv.aax4489"},{"key":"5300_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.actatropica.2004.06.002","volume":"92","author":"CC John","year":"2004","unstructured":"John CC, Koech DK, Sumba PO, Ouma JH. Risk of Plasmodium falciparum infection during a malaria epidemic in highland Kenya, 1997. Acta Trop. 2004;92:55\u201361.","journal-title":"Acta Trop"},{"key":"5300_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4269\/ajtmh.2012.11-0530","volume":"87","author":"MA Rolfes","year":"2012","unstructured":"Rolfes MA, McCarra M, Magak NG, Ernst KC, Dent AE, Lindblade KA, et al. Development of clinical immunity to malaria in highland areas of low and unstable transmission. Am J Trop Med Hyg. 2012;87:806\u201312.","journal-title":"Am J Trop Med Hyg"},{"key":"5300_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1475-2875-7-40","volume":"7","author":"JM Cohen","year":"2008","unstructured":"Cohen JM, Ernst KC, Lindblade KA, Vulule JM, John CC, Wilson ML. Topography-derived wetness indices are associated with household-level malaria risk in two communities in the western Kenyan highlands. Malar J. 2008;7:40.","journal-title":"Malar J"},{"key":"5300_CR27","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3201\/eid1512.090627","volume":"15","author":"CC John","year":"2009","unstructured":"John CC, Riedesel MA, Magak NG, Lindblade KA, Menge DM, Hodges JS, et al. Possible interruption of malaria transmission, highland Kenya, 2007\u20132008. Emerg Infect Dis. 2009;15:1917\u201324.","journal-title":"Emerg Infect Dis"},{"key":"5300_CR28","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.4269\/ajtmh.18-0805","volume":"103","author":"KES Hamre","year":"2020","unstructured":"Hamre KES, Ondigo BN, Hodges JS, Dutta S, Theisen M, Ayodo G, et al. Antibody correlates of protection from clinical Plasmodium falciparum malaria in an area of low and unstable malaria transmission. Am J Trop Med Hyg. 2020;103:2174\u201382.","journal-title":"Am J Trop Med Hyg"},{"key":"5300_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1475-2875-13-163","volume":"13","author":"AL Mutanda","year":"2014","unstructured":"Mutanda AL, Cheruiyot P, Hodges JS, Ayodo G, Odero W, John CC. Sensitivity of fever for diagnosis of clinical malaria in a Kenyan area of unstable, low malaria transmission. Malar J. 2014;13:163.","journal-title":"Malar J"},{"key":"5300_CR30","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-021-21998-4","volume":"12","author":"GQ Feng","year":"2021","unstructured":"Feng GQ, Wines BD, Kurtovic L, Chan JA, Boeuf P, Mollard V, et al. Mechanisms and targets of Fc gamma-receptor mediated immunity to malaria sporozoites. Nat Commun. 2021;12:1742.","journal-title":"Nat Commun"},{"key":"5300_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032242","volume":"7","author":"SB Reddy","year":"2012","unstructured":"Reddy SB, Anders RF, Beeson JG, F\u00e4rnert A, Kironde F, Berenzon SK, et al. High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria. PLoS ONE. 2012;7: e32242.","journal-title":"PLoS ONE"},{"key":"5300_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/infdis\/jiy170","volume":"218","author":"GQ Feng","year":"2018","unstructured":"Feng GQ, Boyle MJ, Cross N, Chan JA, Roiling L, Osier F, et al. Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional antibodies to multiple parasite strains. J Infect Dis. 2018;218:35\u201343.","journal-title":"J Infect Dis"},{"key":"5300_CR33","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/14760584.2021.1981864","volume":"20","author":"DH Opi","year":"2021","unstructured":"Opi DH, Kurtovic L, Chan JA, Horton JL, Feng GQ, Beeson JG. Multi-functional antibody profiling for malaria vaccine development and evaluation. Expert Rev Vaccines. 2021;20:1257\u201372.","journal-title":"Expert Rev Vaccines"},{"key":"5300_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96381","volume":"2","author":"RO Payne","year":"2017","unstructured":"Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, et al. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight. 2017;2: e96381.","journal-title":"JCI Insight"},{"key":"5300_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijpara.2016.06.002","volume":"47","author":"MJ Boyle","year":"2017","unstructured":"Boyle MJ, Reiling L, Osier FH, Fowkes FJI. Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria. Int J Parasitol. 2017;47:99\u2013104.","journal-title":"Int J Parasitol"},{"key":"5300_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","volume":"24","author":"SJ Draper","year":"2018","unstructured":"Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe. 2018;24:43\u201356.","journal-title":"Cell Host Microbe"},{"key":"5300_CR37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","volume":"37","author":"DI Stanisic","year":"2023","unstructured":"Stanisic DI, Good MF. Malaria vaccines: progress to date. BioDrugs. 2023;37:737\u201356.","journal-title":"BioDrugs"},{"key":"5300_CR38","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41467-021-21775-3","volume":"12","author":"JD Challenger","year":"2021","unstructured":"Challenger JD, Olivera Mesa D, Da DF, Yerbanga RS, Lef\u00e8vre T, Cohuet A, et al. Predicting the public health impact of a malaria transmission-blocking vaccine. Nat Commun. 2021;12:1494.","journal-title":"Nat Commun"},{"key":"5300_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146221","volume":"131","author":"SA Healy","year":"2021","unstructured":"Healy SA, Anderson C, Swihart BJ, Mwakingwe A, Gabriel EE, Decederfelt H, et al. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. J Clin Invest. 2021;131: e146221.","journal-title":"J Clin Invest"},{"key":"5300_CR40","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.immuni.2023.01.013","volume":"56","author":"D Ivanochko","year":"2023","unstructured":"Ivanochko D, Fabra-Garc\u00eda A, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Newton J, et al. Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230. Immunity. 2023;56:420-432.e7.","journal-title":"Immunity"},{"key":"5300_CR41","doi-asserted-by":"crossref","unstructured":"Jin J, Tarrant RD, Bolam EJ, Angell-Manning P, Soegaard M, Pattinson DJ, et al. Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. NPJ Vaccines. 2018;3:32.","DOI":"10.1038\/s41541-018-0071-7"},{"key":"5300_CR42","doi-asserted-by":"crossref","unstructured":"Chan JA, Drew DR, Reiling L, Lisboa-Pinto A, Dinko B, Sutherland CJ, et al. Low Levels of Human Antibodies to Gametocyte-Infected Erythrocytes Contrasts the PfEMP1-Dominant Response to Asexual Stages in P. falciparum Malaria. Front Immunol. 2018;9:3126.","DOI":"10.3389\/fimmu.2018.03126"},{"key":"5300_CR43","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.4049\/jimmunol.1001555","volume":"185","author":"L Reiling","year":"2010","unstructured":"Reiling L, Richards JS, Fowkes FJ, Barry AE, Triglia T, Chokejindachai W, et al. Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J Immunol. 2010;185:6157\u201367.","journal-title":"J Immunol"},{"key":"5300_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045253","volume":"7","author":"L Reiling","year":"2012","unstructured":"Reiling L, Richards JS, Fowkes FJ, Wilson DW, Chokejindachai W, Barry AE, et al. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. PLoS ONE. 2012;7: e45253.","journal-title":"PLoS ONE"},{"key":"5300_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221733","volume":"14","author":"JA Chan","year":"2019","unstructured":"Chan JA, Wetzel D, Reiling L, Miura K, Drew DR, Gilson PR, et al. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity. PLoS ONE. 2019;14: e0221733.","journal-title":"PLoS ONE"},{"key":"5300_CR46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/1475-2875-11-427","volume":"11","author":"BN Ondigo","year":"2012","unstructured":"Ondigo BN, Park GS, Gose SO, Ho BM, Ochola LA, Ayodo GO, Ofulla AV, John CC. Standardization and validation of a cytometric bead assay to assess antibodies to multiple Plasmodium falciparum recombinant antigens. Malar J. 2012;11:427.","journal-title":"Malar J"},{"key":"5300_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12936-018-2369-3","volume":"17","author":"I Ubillos","year":"2018","unstructured":"Ubillos I, Jimenez A, Vidal M, Bowyer PW, Gaur D, Dutta S, et al. Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG(1\u20134), IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies. Malar J. 2018;17:219.","journal-title":"Malar J"},{"key":"5300_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.vaccine.2020.12.038","volume":"39","author":"R Suau","year":"2021","unstructured":"Suau R, Vidal M, Aguilar R, Ruiz-Olalla G, Vazquez-Santiago M, Jairoce C, et al. RTS, S\/AS01(E) malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial. Vaccine. 2021;39:687\u201398.","journal-title":"Vaccine"},{"key":"5300_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12936-019-2915-7","volume":"18","author":"EO Odhiambo","year":"2019","unstructured":"Odhiambo EO, Datta D, Guyah B, Ayodo G, Ondigo BN, Abong\u2019o BO, John CC, Frosch AEP. HIV infection drives IgM and IgG3 subclass bias in Plasmodium falciparum-specific and total immunoglobulin concentration in Western Kenya. Malar J. 2019;18:297.","journal-title":"Malar J"},{"key":"5300_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/infdis\/jir223","volume":"204","author":"B Greenhouse","year":"2011","unstructured":"Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, et al. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis. 2011;204:19\u201326.","journal-title":"J Infect Dis"},{"key":"5300_CR51","doi-asserted-by":"crossref","unstructured":"Mensah-Brown HE, Aspeling-Jones H, Delimini RK, Asante KP, Amlabu E, Bah SY, et al. Antibody reactivity to merozoite antigens in Ghanaian adults correlates with growth inhibitory activity against Plasmodium falciparum in culture. Open Forum Infect Dis. 2019;6:ofz254.","DOI":"10.1093\/ofid\/ofz254"},{"key":"5300_CR52","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4049\/jimmunol.1300778","volume":"191","author":"JS Richards","year":"2013","unstructured":"Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol. 2013;191:795\u2013809.","journal-title":"J Immunol"},{"key":"5300_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1128\/CVI.05523-11","volume":"19","author":"C Doba\u00f1o","year":"2012","unstructured":"Doba\u00f1o C, Quelhas D, Quint\u00f3 L, Puyol L, Serra-Casas E, Mayor A, et al. Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children. Clin Vaccine Immunol. 2012;19:157\u201366.","journal-title":"Clin Vaccine Immunol"},{"key":"5300_CR54","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1128\/IAI.02398-14","volume":"83","author":"DI Stanisic","year":"2015","unstructured":"Stanisic DI, Fowkes FJ, Koinari M, Javati S, Lin E, Kiniboro B, et al. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect Immun. 2015;83:646\u201360.","journal-title":"Infect Immun"},{"key":"5300_CR55","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.pt.2015.09.007","volume":"32","author":"RJ Pleass","year":"2016","unstructured":"Pleass RJ, Moore SC, Stevenson L, Hviid L. Immunoglobulin M: restrainer of inflammation and mediator of immune evasion by Plasmodium falciparum malaria. Trends Parasitol. 2016;32:108\u201319.","journal-title":"Trends Parasitol"},{"key":"5300_CR56","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.immuni.2015.02.012","volume":"42","author":"MJ Boyle","year":"2015","unstructured":"Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015;42:580\u201390.","journal-title":"Immunity"},{"key":"5300_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243943","volume":"15","author":"MR Walker","year":"2020","unstructured":"Walker MR, Knudsen AS, Partey FD, Bassi MR, Frank AM, Castberg FC, et al. Acquisition and decay of IgM and IgG responses to merozoite antigens after Plasmodium falciparum malaria in Ghanaian children. PLoS ONE. 2020;15: e0243943.","journal-title":"PLoS ONE"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05300-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:57:22Z","timestamp":1741085842000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5300"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05300-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the guidelines established by the Ethical Review Committee of the Kenya Medical Research Institute (KEMRI) Ethical Review Committee and the Indiana University Institutional Review Board. Prior to enrolment, all participants were fully informed about the study and provided written and signed consent in their native language. The study was conducted in accordance with the Declaration of Helsinki, and informed consent was obtained from all the participants. The protocol was approved by the KEMRI Ethical Review Committee and Indiana University Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}